Find a company
"Elecsys® GAAD is an in vitro diagnostic multivariate index assay intended to provide a semi-quantitative result by combining in an algorithm the quantitative measurements of Elecsys® AFP assay and Elecsys® PIVKA‑II assay in human serum and plasma with gender and age. Elecsys® GAAD is intended as an aid in diagnosis of early stage Hepatocellular Carcinoma (HCC).
Elecsys® GAAD is indicated for adults who meet the following criteria: diagnosis of chronic liver disease and recommended for surveillance due to increased risk of developing HCC.
Elecsys® GAAD must be interpreted in conjunction with other diagnostic findings and clinical information in accordance with standard clinical management guidelines."
| Project | Implementation of Elecsys® GAAD clinical algorithm for the early detection of Hepatocellular Carcinoma (HCC) in routine practice |
|---|---|
| Description |
With Roche Diagnostics Ltd, this 18-month project will explore the use of an innovative solution, called Elecsys®GAAD, to improve early Hepatocellular Carcinoma (HCC) detection. Elecsys®GAAD is a fully regulated, accurate test that combines blood tests with gender and age. If raised, it can suggest the presence of HCC. It will be used alongside routine surveillance tests to see if it can help in finding HCC earlier so patients have the best chance of surviving this cancer. |
| Funding | £ 1,006,075 |
| Competition | NHS Cancer Programme – Innovation Open Call – Competition 2 |
| Competition Date | February 2022 |
| Categories | Cancer |
"Elecsys® GAAD is an in vitro diagnostic multivariate index assay intended to provide a semi-quantitative result by combining in an algorithm the quantitative measurements of Elecsys® AFP assay and Elecsys® PIVKA‑II assay in human serum and plasma with gender and age. Elecsys® GAAD is intended as an aid in diagnosis of early stage Hepatocellular Carcinoma (HCC).
Elecsys® GAAD is indicated for adults who meet the following criteria: diagnosis of chronic liver disease and recommended for surveillance due to increased risk of developing HCC.
Elecsys® GAAD must be interpreted in conjunction with other diagnostic findings and clinical information in accordance with standard clinical management guidelines."
| Project | SEARCH: Implementing and evaluating screening for Hodgkin lymphoma survivors within the NHS Lung Cancer Screening Programme |
|---|---|
| Description |
The University of Manchester and NIHR Manchester Biomedical Research Centre. Using population level data to model lung cancer risk in Hodgkin lymphoma survivors, researchers at The NIHR Manchester Biomedical Research Centre, The University of Manchester and University of Oxford developed extended criteria and a modified risk calculator to identify Hodgkin lymphoma survivors at increased risk of developing lung cancer as a late complication of previous cancer treatment. The SEARCH project funded by SBRI Healthcare will implement and evaluate this technology for identification and screening of high risk Hodgkin lymphoma survivors within the NHS Lung Cancer Screening Programme. Results will generate evidence to support routine adoption. |
| Funding | £ 1,294,330 |
| Competition | NHS Cancer Programme - Innovation Open Call 3 |
| Competition Date | April 2024 |
| Categories | Cancer |